Fig. 3From: Unveiling the efficacy and safety of Erenumab, a monoclonal antibody targeting calcitonin gene-related peptide (CGRP) receptor, in patients with chronic and episodic migraine: a GRADE-assessed systematic review and meta-analysis of randomized clinical trials with subgroup analysisComparison of Erenumab vs placebo in terms of A) MMD, B) MSMD, C) HIT-6 at three monthsBack to article page